GlassScriptPhysician profile
Martin Barnes
NPI 1730583089
$2,364.40
in general payments reported to CMS, 2019-2025
35 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.99 · 2022: $118 · 2023: $401 · 2024: $642 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.03 |
| Education | $107.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $345.15 | 2023-2025 | Darzalex, Imbruvica, Talvey |
| Genzyme Corporation | $263.66 | 2022-2024 | |
| Incyte Corporation | $179.81 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Astrazeneca Pharmaceuticals LP | $178.57 | 2023-2025 | Calquence, Imfinzi |
| Emd Serono, INC. | $176.64 | 2024 | |
| Eisai INC. | $138.86 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.27 | 2025 | Fruzaqla, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $84.54 | 2024-2025 | Libtayo |
| Beone Medicines USA, INC. | $71.35 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $64.17 | 2024-2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $62.15 | 2025 | |
| Myriad Genetic Laboratories, INC. | $59.30 | 2024 | Bracanalysis Cdx |
| Genentech USA, INC. | $58.34 | 2025 | Phesgo, Polivy |
| Daiichi Sankyo INC. | $55.46 | 2024-2025 | Enhertu, Datroway |
| Exelixis INC. | $53.10 | 2025 | Cabometyx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $38.31 | 2024-2025 | Trodelvy |
| Stemline Therapeutics INC. | $36.67 | 2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $35.68 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Immunocore Limited | $34.53 | 2025 | Kimmtrak |
| Array Biopharma INC | $32.67 | 2025 | Braftovi, Tukysa, Mektovi |
| Tersera Therapeutics LLC | $26.70 | 2025 | Quzyttir |
| Lilly USA, LLC | $24.00 | 2024 | |
| Dendreon Pharmaceuticals LLC | $23.41 | 2025 | Provenge |
| Merck Sharp & Dohme LLC | $22.84 | 2025 | Keytruda |
| Cti Biopharma Corp. | $22.24 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $20.27 | 2025 | Pyrukynd |
| Hologic Sales and Service, LLC | $20.16 | 2025 | Magseed |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.33 | 2025 | |
| Celgene Corporation | $18.23 | 2025 | Reblozyl |
| Karyopharm Therapeutics INC. | $17.18 | 2025 | Xpovio |
| Glaxosmithkline, LLC. | $16.72 | 2025 | Blenrep, Ojjaara |
| Aveo Pharmaceuticals, INC. | $16.67 | 2025 | |
| Pfizer INC. | $16.03 | 2025 | |
| Novocure INC. | $15.88 | 2025 | Optune Lua (Novottf-200t) |
| Sumitomo Pharma America, INC. | $13.51 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.